• 1
    Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:26442650.
  • 2
    Van Haeften TW, Pimenta W, Mitrakou A, et al. Disturbances in beta-cell function in impaired fasting glycemia. Diabetes. 2002;51: S265S270.
  • 3
    Porte D Jr. Mechanisms for hyperglycemia in the metabolic syndrome. The key role of beta-cell dysfunction. Ann N Y Acad Sci. 1999;892:7383.
  • 4
    Ahren B, Pacini G. Islet adaptation to insulin resistance: mechanism and implications for intervention. Diabetes Obes Metab. 2005;7:28.
  • 5
    Hanley AJ, Wagenknecht LE, D'Agostino RB Jr, et al. Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes. 2003;52:27402747.
  • 6
    Porte D Jr, Khan SE. The key role of islet dysfunction in type II diabetes mellitus. Clin Invest Med. 1995;18:247254.
  • 7
    Bruning JC, Winnay S, Bonner-Weir SI, et al. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell. 1997;88:561572.
  • 8
    Therauchi Y, Sakura H, Yasuda K, et al. Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J Biol Chem. 1995;270:3025330256.
  • 9
    Vaag A, Heriksen JE, Madsbad S, et al. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;95:690698.
  • 10
    Stone LM, Kahn SE, Fujimoto WY. et al. A variation at position −30 of the beta-cell glucokinase gene promoter is associated with reduced beta-cell function in middle-aged Japanese-American men. Diabetes. 1996;45:422428.
  • 11
    McMillen IC, Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity and programming. Physiol Rev. 2005;85:571633.
  • 12
    Simmons RA, Suponitsky-Kroyter I, Selak MA. Progressive accumulation of mitochondrial DNA mutations and decline in mitochondrial function lead to beta-cell failure. J Biol Chem. 2005;280:2878528791.
  • 13
    Van Assche FA, De Prins F, Aerts L, et al. The endocrine pancreas in small-for-dates infants. Br J Obstet Gynaecol. 1977;84:751753.
  • 14
    Jensen CB, Storgaard H, Dela F. et al. Early differential defects of insulin secretion and action in 19-year-old caucasian men who had low birth weight. Diabetes. 2002;51:12711280.
  • 15
    Beringue F, Blondeau B, Castellotti MC. et al. Endocrine pancreas development in growth-retarded human fetuses. Diabetes. 2002;51:385391.
  • 16
    Srinivasan M, Laychock SG, Hill Dj, et al. Neonatal nutrition: metabolic programming of pancreatic islets and obesity. Exp Biol Med (Maywood). 2003;228:1523.
  • 17
    Ashdown-Lambert JR. A review of low birth weight: predictors, precursors and morbidity outcomes. J R Soc Health. 2005;125:7683.
  • 18
    Shuldiner AR, McLenithan JC. Genes and pathophysiology of type 2 diabetes: more than just the Randle cycle all over. J Clin Invest. 2004;114:14141417.
  • 19
    Seufert J, Weir GC, Habener JF. Differential expression of the insulin gene transcriptional repressor CCAAT/enhancer-binding protein beta and transactivator islet duodenum homeobox-1 in rat pancreatic beta cells during the development of diabetes mellitus. J Clin Invest. 1998;101:25282539.
  • 20
    Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307:384387.
  • 21
    Tajiri Y, Moller C, Grill V. Long-term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosilation end products inhibits B-cell function. Endocrinolog y. 1997;138:273280.
  • 22
    Tanaka Y, Gleason CE, Tran PO. et al. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci U S A. 1999;96:1085710862.
  • 23
    Robertson RP, Harmon J, Tran PO, et al. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52:581587.
  • 24
    Gremlich S, Bonny C, Waeber G, et al. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin and somatostatin levels. J Biol Chem. 1997;272:3026130269.
  • 25
    Lameloise N, Muzzin P, Prentki M. et al. Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes. 2001;50:803809.
  • 26
    Carlsson C, Borg LA, Welsh N. Sodium palmitate induces partial mitochondrial uncoupling and reactive oxygen species in rat pancreatic islets in vitro. Endocrinology. 1999;140:34223428.
  • 27
    Patane G, Piro S, Rabuazzo AM. et al. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta cells. Diabetes. 2000;49:735740.
  • 28
    Robertson RP, Harmon J, Tran PO, et al. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53:S119S124.
  • 29
    Jacqueminet S, Briaud I, Rouault C. et al. Inhibition of insulin gene expression by long-term exposure of pancreatic beta cells to palmitate is dependent on the presence of a stimulatory glucose concentration. Metabolism. 2000;49:532536.
  • 30
    Harmon JS, Gleason CE, Tanaka Y. et al. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decresed insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes. 2001;50:24812486.
  • 31
    Donath MY, Gross DJ, Cerasi E. et al. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes. 1999;48:738744.
  • 32
    Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102110.
  • 33
    Maedler K, Sergeev P, Ris F. et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110:851860.
  • 34
    Maedler K, Spinas GA, Lehmann R. et al. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes. 2001;50:16831690.
  • 35
    Donath MY, Ehses JA, Maedler K, et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes. 2005;54:S108S113.
  • 36
    Maedler K, Fontana A, Ris F. et al. FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication. Proc Natl Acad Sci U S A. 2002;99:82368241.
  • 37
    Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:25482556.
  • 38
    Maedler K, Serggev P, Ehses JA. et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A. 2004;101:81388143.
  • 39
    Roehrich ME, Mooser V, Lenain V. et al. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem. 2003;278:1836818375.
  • 40
    Hayden MR, Stump CS, Sowers JR. Organ involvement in the cardiometabolic syndrome. J Cardiometabolic Syndr. 2006;1:1624.
  • 41
    Zeender E, Maedler K, Bosco D. et al. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab. 2004;89:50595066.
  • 42
    Araki E, Oyadomari S, Mori M. Endoplasmic reticulum stress and the development of diabetes mellitus. Intern Med. 2003;42:714.
  • 43
    Ozcan U, Cao Q, Yilmaz E. et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes mellitus. Science. 2004;306:457461.
  • 44
    Kitabchi AE, Temprosa M, Knowler WC. et al., for The Diabetes Prevention Program Research Group. Role of insulin secretion and insulin sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54:24042414.
  • 45
    Buchanan TA, Xiang AH, Peters RK. et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:27962803.
  • 46
    Matsui J, Therauchi Y, Kubota N. et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor—gamma-deficient mice on a high-fat diet. Diabetes. 2004;53:28442854.
  • 47
    Lin CY, Gurlo T, Haataja L. et al. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by phosphatidylinostol 3'-kinase-dependent pathway. J Clin Endocrinol Metab. 2005;90:66786686.
  • 48
    Li L, El-Kholy W, Rhodes CJ, et al. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia. 2005;48:13391349.
  • 49
    Hansen PA, Corbett HA. Incretin hormones and insulin sensitivity. Trends Endocrinol Metab. 2005;16:135136.
  • 50
    Stoffers DA, Desai BM, DeLeon DD, et al. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes. 2003;52:734740.